Siksi Mircera- hoitoon ei pidä siirtyä, jos potilaalla epäillään tai on todettu erytropoietiinivasta- aineita. ###>These antibodies have been shown to cross-react with all ESAs, and patients suspected or confirmed to have antibodies to erythropoietin should not be switched to MIRCERA.